Published in PLoS Comput Biol on October 06, 2011
A unified view of "how allostery works". PLoS Comput Biol (2014) 1.59
Effects of oncogenic mutations on the conformational free-energy landscape of EGFR kinase. Proc Natl Acad Sci U S A (2013) 0.99
Principles of allosteric interactions in cell signaling. J Am Chem Soc (2014) 0.97
Allosteric communication across the native and mutated KIT receptor tyrosine kinase. PLoS Comput Biol (2012) 0.94
The energy landscape analysis of cancer mutations in protein kinases. PLoS One (2011) 0.86
The spatial structure of cell signaling systems. Phys Biol (2013) 0.86
An automated approach to network features of protein structure ensembles. Protein Sci (2013) 0.85
Probing molecular mechanisms of the Hsp90 chaperone: biophysical modeling identifies key regulators of functional dynamics. PLoS One (2012) 0.85
Structural signature of the G719S-T790M double mutation in the EGFR kinase domain and its response to inhibitors. Sci Rep (2014) 0.85
The designability of protein switches by chemical rescue of structure: mechanisms of inactivation and reactivation. J Am Chem Soc (2013) 0.84
Designing allosteric control into enzymes by chemical rescue of structure. J Am Chem Soc (2012) 0.83
Towards a Molecular Understanding of the Link between Imatinib Resistance and Kinase Conformational Dynamics. PLoS Comput Biol (2015) 0.83
Differential modulation of functional dynamics and allosteric interactions in the Hsp90-cochaperone complexes with p23 and Aha1: a computational study. PLoS One (2013) 0.81
Computational study of the "DFG-flip" conformational transition in c-Abl and c-Src tyrosine kinases. J Phys Chem B (2015) 0.81
Simulating molecular mechanisms of the MDM2-mediated regulatory interactions: a conformational selection model of the MDM2 lid dynamics. PLoS One (2012) 0.80
The SH2 domain regulates c-Abl kinase activation by a cyclin-like mechanism and remodulation of the hinge motion. PLoS Comput Biol (2014) 0.80
Structural bioinformatics and protein docking analysis of the molecular chaperone-kinase interactions: towards allosteric inhibition of protein kinases by targeting the hsp90-cdc37 chaperone machinery. Pharmaceuticals (Basel) (2013) 0.79
Structure-functional prediction and analysis of cancer mutation effects in protein kinases. Comput Math Methods Med (2014) 0.79
Hotspot mutations in KIT receptor differentially modulate its allosterically coupled conformational dynamics: impact on activation and drug sensitivity. PLoS Comput Biol (2014) 0.79
Dynamic multiprotein assemblies shape the spatial structure of cell signaling. Prog Biophys Mol Biol (2014) 0.78
Computational study on the inhibitor binding mode and allosteric regulation mechanism in hepatitis C virus NS3/4A protein. PLoS One (2014) 0.76
Dissecting protein architecture with communication blocks and communicating segment pairs. BMC Bioinformatics (2016) 0.75
Identification of the binding site of an allosteric ligand using STD-NMR, docking, and CORCEMA-ST calculations. ChemMedChem (2013) 0.75
Discovery of Novel Allosteric Eg5 Inhibitors Through Structure-Based Virtual Screening. Chem Biol Drug Des (2016) 0.75
Allosteric Communication Networks in Proteins Revealed through Pocket Crosstalk Analysis. ACS Cent Sci (2017) 0.75
Design of Elastic Networks with Evolutionary Optimized Long-Range Communication as Mechanical Models of Allosteric Proteins. Biophys J (2017) 0.75
The Protein Data Bank. Nucleic Acids Res (2000) 187.10
Scalable molecular dynamics with NAMD. J Comput Chem (2005) 59.49
All-atom empirical potential for molecular modeling and dynamics studies of proteins. J Phys Chem B (1998) 54.00
ON THE NATURE OF ALLOSTERIC TRANSITIONS: A PLAUSIBLE MODEL. J Mol Biol (1965) 46.35
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med (2005) 26.35
Comparative protein structure modeling of genes and genomes. Annu Rev Biophys Biomol Struct (2000) 17.81
Comparison of experimental binding data and theoretical models in proteins containing subunits. Biochemistry (1966) 16.43
A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol (2008) 14.74
Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med (2008) 13.54
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell (2002) 13.03
Cell signaling by receptor tyrosine kinases. Cell (2010) 12.39
A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol (2005) 12.22
Overriding imatinib resistance with a novel ABL kinase inhibitor. Science (2004) 11.83
Essential dynamics of proteins. Proteins (1993) 11.56
The architecture of complex weighted networks. Proc Natl Acad Sci U S A (2004) 11.53
An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell (2006) 10.28
Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science (2000) 9.29
Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer (2009) 9.26
Evolutionarily conserved pathways of energetic connectivity in protein families. Science (1999) 9.12
Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex. Nature (1995) 9.03
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A (2008) 8.08
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell (2005) 7.99
AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell (2009) 6.97
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene (2008) 6.82
Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat Biotechnol (2007) 6.56
A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res (2004) 6.53
Evolutionarily conserved networks of residues mediate allosteric communication in proteins. Nat Struct Biol (2003) 6.50
In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res (2005) 5.98
Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell (2007) 5.95
PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res (2007) 5.45
Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell (2003) 5.44
Rational design of inhibitors that bind to inactive kinase conformations. Nat Chem Biol (2006) 5.03
Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy. Cancer Cell (2007) 4.85
Development and current status of the CHARMM force field for nucleic acids. Biopolymers (2001) 4.80
Mechanism for activation of the EGF receptor catalytic domain by the juxtamembrane segment. Cell (2009) 4.78
Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. Nat Struct Mol Biol (2004) 4.40
Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res (2002) 4.19
Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism. Proc Natl Acad Sci U S A (2006) 4.09
Features of selective kinase inhibitors. Chem Biol (2005) 4.07
Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. Nat Genet (2005) 4.00
Extracting the multiscale backbone of complex weighted networks. Proc Natl Acad Sci U S A (2009) 3.94
Structural basis of cyclin-dependent kinase activation by phosphorylation. Nat Struct Biol (1996) 3.81
Crystal structure of an activated Akt/protein kinase B ternary complex with GSK3-peptide and AMP-PNP. Nat Struct Biol (2002) 3.77
Allostery and cooperativity revisited. Protein Sci (2008) 3.70
Allosteric regulation and catalysis emerge via a common route. Nat Chem Biol (2008) 3.62
Protein kinases: evolution of dynamic regulatory proteins. Trends Biochem Sci (2010) 3.61
Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood (2007) 3.59
Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors. Biochem J (2005) 3.58
Molecular mechanism for the regulation of protein kinase B/Akt by hydrophobic motif phosphorylation. Mol Cell (2002) 3.53
Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors. Bioorg Med Chem Lett (2005) 3.50
A Src-like inactive conformation in the abl tyrosine kinase domain. PLoS Biol (2006) 3.40
Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature (2010) 3.39
The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res (2006) 3.28
Dynamic coupling between the SH2 and SH3 domains of c-Src and Hck underlies their inactivation by C-terminal tyrosine phosphorylation. Cell (2001) 3.25
Allostery: absence of a change in shape does not imply that allostery is not at play. J Mol Biol (2008) 3.24
Activation of tyrosine kinases by mutation of the gatekeeper threonine. Nat Struct Mol Biol (2008) 3.18
Allosteric inhibitors of Bcr-abl-dependent cell proliferation. Nat Chem Biol (2006) 2.96
The juxtamembrane region of the EGF receptor functions as an activation domain. Mol Cell (2009) 2.90
Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance. Proc Natl Acad Sci U S A (2005) 2.85
Mechanism of activation and inhibition of the HER4/ErbB4 kinase. Structure (2008) 2.79
Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface. Nature (2007) 2.78
The hallmark of AGC kinase functional divergence is its C-terminal tail, a cis-acting regulatory module. Proc Natl Acad Sci U S A (2007) 2.65
Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood (2003) 2.61
The T790M "gatekeeper" mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor. Mol Cancer Ther (2008) 2.58
Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3. Proc Natl Acad Sci U S A (2009) 2.55
Structural basis for the selective inhibition of JNK1 by the scaffolding protein JIP1 and SP600125. EMBO J (2004) 2.53
A helix scaffold for the assembly of active protein kinases. Proc Natl Acad Sci U S A (2008) 2.51
Binding sites in Escherichia coli dihydrofolate reductase communicate by modulating the conformational ensemble. Proc Natl Acad Sci U S A (2000) 2.47
Small-world view of the amino acids that play a key role in protein folding. Phys Rev E Stat Nonlin Soft Matter Phys (2002) 2.43
Catalytic control in the EGF receptor and its connection to general kinase regulatory mechanisms. Mol Cell (2011) 2.35
The origin of allosteric functional modulation: multiple pre-existing pathways. Structure (2009) 2.33
Intrinsic dynamics of enzymes in the unbound state and relation to allosteric regulation. Curr Opin Struct Biol (2007) 2.28
Did protein kinase regulatory mechanisms evolve through elaboration of a simple structural component? J Mol Biol (2005) 2.28
Organization of the SH3-SH2 unit in active and inactive forms of the c-Abl tyrosine kinase. Mol Cell (2006) 2.28
A general strategy for creating "inactive-conformation" abl inhibitors. Chem Biol (2006) 2.27
Identification of a new JNK inhibitor targeting the JNK-JIP interaction site. Proc Natl Acad Sci U S A (2008) 2.26
Large-scale allosteric conformational transitions of adenylate kinase appear to involve a population-shift mechanism. Proc Natl Acad Sci U S A (2007) 2.24
A dynamic model for the allosteric mechanism of GroEL. J Mol Biol (2000) 2.20
Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance. Chem Biol Drug Des (2010) 2.19
A conserved protonation-dependent switch controls drug binding in the Abl kinase. Proc Natl Acad Sci U S A (2008) 2.18
Protein allostery, signal transmission and dynamics: a classification scheme of allosteric mechanisms. Mol Biosyst (2009) 2.18
Role of a novel PH-kinase domain interface in PKB/Akt regulation: structural mechanism for allosteric inhibition. PLoS Biol (2009) 2.15
Allosteric changes in protein structure computed by a simple mechanical model: hemoglobin T<-->R2 transition. J Mol Biol (2003) 2.14
Solution conformations and dynamics of ABL kinase-inhibitor complexes determined by NMR substantiate the different binding modes of imatinib/nilotinib and dasatinib. J Biol Chem (2008) 2.09
The allosteric mechanism of the chaperonin GroEL: a dynamic analysis. Proc Natl Acad Sci U S A (1998) 2.07
Software news and updates. Carma: a molecular dynamics analysis program. J Comput Chem (2006) 2.04
Residues crucial for maintaining short paths in network communication mediate signaling in proteins. Mol Syst Biol (2006) 1.98
Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680. Cancer Res (2006) 1.98
Low-frequency normal modes that describe allosteric transitions in biological nanomachines are robust to sequence variations. Proc Natl Acad Sci U S A (2006) 1.90
Dynamics of allosteric transitions in GroEL. Proc Natl Acad Sci U S A (2006) 1.88
c-Src binds to the cancer drug imatinib with an inactive Abl/c-Kit conformation and a distributed thermodynamic penalty. Structure (2007) 1.87
Trapping moving targets with small molecules. Science (2009) 1.86
Small-world communication of residues and significance for protein dynamics. Biophys J (2004) 1.84
Defining the conserved internal architecture of a protein kinase. Biochim Biophys Acta (2009) 1.76
Protein elastic network models and the ranges of cooperativity. Proc Natl Acad Sci U S A (2009) 1.76
Small-world network approach to identify key residues in protein-protein interaction. Proteins (2005) 1.75
On the convergence of the conformational coordinates basis set obtained by the essential dynamics analysis of proteins' molecular dynamics simulations. Proteins (1999) 1.75
Structure and clinical relevance of the epidermal growth factor receptor in human cancer. J Clin Oncol (2008) 1.73
Local motions in a benchmark of allosteric proteins. Proteins (2007) 1.71
Mapping the conformational transition in Src activation by cumulating the information from multiple molecular dynamics trajectories. Proc Natl Acad Sci U S A (2009) 1.70
Energy landscape theory, funnels, specificity, and optimal criterion of biomolecular binding. Phys Rev Lett (2003) 2.07
Elucidation of the Hsp90 C-terminal inhibitor binding site. ACS Chem Biol (2011) 1.19
Hierarchical modeling of activation mechanisms in the ABL and EGFR kinase domains: thermodynamic and mechanistic catalysts of kinase activation by cancer mutations. PLoS Comput Biol (2009) 1.15
Sequence and structure signatures of cancer mutation hotspots in protein kinases. PLoS One (2009) 1.14
Sequence recognition of alpha-LFA-1-derived peptides by ICAM-1 cell receptors: inhibitors of T-cell adhesion. Chem Biol Drug Des (2007) 0.86
The energy landscape analysis of cancer mutations in protein kinases. PLoS One (2011) 0.86
Probing molecular mechanisms of the Hsp90 chaperone: biophysical modeling identifies key regulators of functional dynamics. PLoS One (2012) 0.85
Differential modulation of functional dynamics and allosteric interactions in the Hsp90-cochaperone complexes with p23 and Aha1: a computational study. PLoS One (2013) 0.81
Integrating ligand-based and protein-centric virtual screening of kinase inhibitors using ensembles of multiple protein kinase genes and conformations. J Chem Inf Model (2012) 0.80
Experimentally guided structural modeling and dynamics analysis of Hsp90-p53 interactions: allosteric regulation of the Hsp90 chaperone by a client protein. J Chem Inf Model (2013) 0.76
Impact of early pandemic stage mutations on molecular dynamics of SARS-CoV-2 M. J Chem Inf Model (2020) 0.75